Irritable Bowel Syndrome
Tegaserod improves work and daily activity in IBS patients with constipation
Published in Gastroenterology Week, November 14th, 2005
"Tegaserod is a promotility agent with proven efficacy and safety" in such patients, according to scientists in the United States, who conducted a study "to assess tegaserod's effect on work productivity and daily activity."
"Women, 18-65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicenter study of tegaserod 6 mg b.d. or placebo," explained M.C. Reilly and coauthors at Margaret Reilly Associates, Inc. in New York. "Productivity loss and daily activity...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
More Articles from Gastroenterology Week
- Cancer Risk Factors
Patients with gallstones develop gallbladder cancer at an earlier age - Gastroesophageal Reflux
"Silent" nighttime acid reflux symptoms can cause poor sleep and sleep apnea - Surgical Techniques
Trends in ablative techniques for Barrett esophagus are investigated - Adverse Drug Reaction
Tysabri safety evaluation complete; no new confirmed cases of PML - Allergy & Immunology
Hepatitis C virus therapy alters the efforts of natural killer T cells - Angiography
Researchers detail new studies and findings in the area of angiography - More from this issue of Gastroenterology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
